Tdam USA Inc. Trims Holdings in Johnson & Johnson (JNJ)
Tdam USA Inc. lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 3.6% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 349,274 shares of the company’s stock after selling 13,157 shares during the quarter. Johnson & Johnson makes up about 2.4% of Tdam USA Inc.’s investment portfolio, making the stock its 4th biggest position. Tdam USA Inc.’s holdings in Johnson & Johnson were worth $46,326,000 as of its most recent SEC filing.
Several other institutional investors have also modified their holdings of the business. Baker Ellis Asset Management LLC raised its position in shares of Johnson & Johnson by 0.4% in the 2nd quarter. Baker Ellis Asset Management LLC now owns 33,191 shares of the company’s stock worth $4,391,000 after buying an additional 143 shares during the period. Beach Investment Management LLC. raised its position in shares of Johnson & Johnson by 1,256.6% in the 2nd quarter. Beach Investment Management LLC. now owns 286,648 shares of the company’s stock worth $37,921,000 after buying an additional 265,518 shares during the period. WealthTrust Axiom LLC raised its position in shares of Johnson & Johnson by 1.3% in the 2nd quarter. WealthTrust Axiom LLC now owns 16,085 shares of the company’s stock worth $2,127,000 after buying an additional 200 shares during the period. Founders Financial Securities LLC purchased a new position in shares of Johnson & Johnson in the 2nd quarter worth $743,000. Finally, Peak Asset Management LLC raised its position in shares of Johnson & Johnson by 2.9% in the 2nd quarter. Peak Asset Management LLC now owns 13,304 shares of the company’s stock worth $1,760,000 after buying an additional 375 shares during the period. 65.93% of the stock is currently owned by institutional investors.
Shares of Johnson & Johnson (NYSE JNJ) opened at $139.10 on Thursday. The firm has a market capitalization of $374,742.69, a P/E ratio of 19.54, a PEG ratio of 2.83 and a beta of 0.82. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a twelve month low of $109.32 and a twelve month high of $144.35.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.80 by $0.10. The company had revenue of $19.65 billion for the quarter, compared to analysts’ expectations of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.68 earnings per share. sell-side analysts forecast that Johnson & Johnson will post 7.28 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be issued a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, November 27th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.42%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 58.33%.
WARNING: This piece of content was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright legislation. The correct version of this piece of content can be read at https://www.dailypolitical.com/2017/11/16/tdam-usa-inc-trims-holdings-in-johnson-johnson-jnj.html.
Several research analysts recently weighed in on the company. Citigroup Inc. increased their target price on Johnson & Johnson from $140.00 to $149.00 and gave the stock a “buy” rating in a research report on Monday, October 23rd. Vetr upgraded Johnson & Johnson from a “sell” rating to a “hold” rating and set a $137.71 price target for the company in a report on Monday, October 30th. Leerink Swann reiterated an “outperform” rating and issued a $165.00 price target (up from $150.00) on shares of Johnson & Johnson in a report on Wednesday, October 18th. Royal Bank Of Canada increased their price target on Johnson & Johnson from $144.00 to $147.00 and gave the company an “outperform” rating in a report on Wednesday, October 18th. Finally, Stifel Nicolaus increased their price target on Johnson & Johnson from $140.00 to $142.00 and gave the company a “hold” rating in a report on Wednesday, October 18th. Four investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $143.70.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.